Yahoo Finance [Yahoo! Finance]
Sutro Biopharma, Inc. (NASDAQ: STRO) was given a new $2.00 price target on by analysts at Piper Sandler.
Sutro Biopharma, Inc. (NASDAQ: STRO) was downgraded by analysts at Piper Sandler from a "strong-buy" rating to a "hold" rating.
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock, down previously from $12.00.
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025